Similar to the overall participant population, no improvement in survival was observed in the nivolumab plus ipilimumab arm across key subgroups with the exception of a numerical trend toward improved PFS observed in the exploratory tumor PDL1 ≥ 50% subgroup analysis.
← all excerpts
Nivolumab plus chemoradiotherapy followed by nivolumab with or without ipilimumab for untreated locally advanced stage III NSCLC: a randomized phase 3 trial.
1
—
—